Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Zanosar Generic Name & Formulations
Legal Class
Rx
General Description
Streptozocin 1g/vial; pwd for IV inj or infusion after reconstitution/dilution; preservative-free.
Pharmacological Class
Nitrosurea.
How Supplied
Single-use vial—1
Manufacturer
Zanosar Indications
Indications
Symptomatic or progressive metastatic pancreatic islet cell cancer.
Zanosar Dosage and Administration
Adult
1g/m2 IV once weekly for 2 weeks; may repeat weekly; max 1.5g/m2 per dose. Or, 500mg/m2 IV daily for 5 days every 6 weeks until max benefit or toxicity.
Children
Not recommended.
Zanosar Contraindications
Not Applicable
Zanosar Boxed Warnings
Boxed Warning
Should be administered under the supervision of an experienced physician. Have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and toxicity. Mutagenic, tumorigenic, or carcinogenic.
Zanosar Warnings/Precautions
Warnings/Precautions
Renal dysfunction or disease. Monitor renal function (eg, urinalysis, BUN, creatinine, electrolytes) before, weekly during, and for 4 weeks after therapy; discontinue or reduce dose if significant renal toxicity occurs (see full labeling). Obtain CBCs, liver function tests weekly. Avoid extravasation. Ensure adequate hydration. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended.
Zanosar Pharmacokinetics
See Literature
Zanosar Interactions
Interactions
Avoid concomitant nephrotoxic agents. Additive toxicity with other cytotoxic drugs. Severe bone marrow toxicity with doxorubicin. Phenytoin may reduce cytotoxicity.
Zanosar Adverse Reactions
Adverse Reactions
GI upset (may be severe); hematological, hepatic and renal (cumulative and dose-related; may be fatal) toxicity; glucose intolerance, nephrogenic diabetes insipidus, inj site reactions, CNS effects (eg, confusion, lethargy, depression).
Zanosar Clinical Trials
See Literature
Zanosar Note
Not Applicable
Zanosar Patient Counseling
See Literature
